

EVOTEC WINS AWARD FOR "SUSTAINED EXCELLENCE" AT DELOITTE'S TECHNOLOGY FAST 50

Hamburg, Germany, 09 November 2018:

Evotec AG (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that the company has won one of the prestigious "Technology Fast 50" awards with which Deloitte honours the fastest-growing innovation drivers within the technology sector.

At yesterday's award ceremony, Evotec received the prize for "Sustained Excellence" which recognises the Company's long-term growth, innovation capability, entrepreneurial spirit, as well as its sustainable corporate management. The "Sustained Excellence" award distinguishes companies which are financially successful and are characterised by other excellent achievements as well. Their evaluation covers competitive advantages, management, attractiveness of the market segment, as well as financial key performance indicators.

Dr Werner Lanthaler, Chief Executive Officer of Evotec, said: "We are very proud to have received this prestigious award. First and foremost this is a commendation for the excellent performance of our workforce and a strong encouragement for our vision and passion for innovation when it comes to the further implementation of our growth strategy."

"Several fast-growing German companies have positioned themselves in future-oriented fields of technology over the past years. This is the work of enterprisers who through their risk tolerance and entrepreneurial spirit were able to consequently put their visions into action", **explains Dr Andreas Gentner, Partner and Head of Technology, Media & Telecommunications EMEA at Deloitte.** "With the Fast 50 Award we want to recognise exceptional entrepreneurial achievements for Germany as a technology location."

ABOUT DELOITTE

Deloitte provides audit, tax, financial advisory and consulting services to public and private clients spanning multiple industries; legal advisory services in Germany are provided by Deloitte Legal. With a globally connected network of member firms in more than 150 countries, Deloitte brings world-class capabilities and high-quality service to clients, delivering the insights they need to address their most complex business challenges. Making an impact that matters – for around 286,000 Deloitte employees this is both a common mission statement and an individual claim. Deloitte refers to Deloitte Touche Tohmatsu Limited (“DTTL”), a “private company limited by guarantee”, its network of member companies and their affiliates. DTTL and each of its member companies are legally independent. DTTL (also called “Deloitte Global”) does not provide services to clients. A more detailed description of DTTL and its member companies can be found on www.deloitte.com/de/UeberUns.

Your Contacts:**Media**

Kristin Ofer

kofer@deloitte.de

Tel: +49 (0)89 29036 6691

Coordination of the Technology Fast 50 competition

Sabrina Melic

smelic@deloitte.de

Tel.: +49 (0)89 29036 8924

ABOUT EVOTEC AG

Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies, academics, patient advocacy groups and venture capitalists. We operate worldwide and our more than 2,400 employees provide the highest quality stand-alone and integrated drug discovery and development solutions. We cover all activities from target-to-clinic to meet the industry's need for innovation and efficiency in drug discovery and development (EVT Execute). The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuronal diseases, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. On this basis, Evotec has built a broad and deep pipeline of approx. 100 co-owned product opportunities at clinical, pre-clinical and discovery stages (EVT Innovate). Evotec has established multiple long-term alliances with partners including Bayer, Boehringer Ingelheim, Celgene, CHDI, Novartis, Novo Nordisk, Pfizer, Sanofi, Takeda, UCB and others. For additional information please go to www.evotec.com and follow us on Twitter [@EvotecAG](https://twitter.com/EvotecAG).

FORWARD LOOKING STATEMENTS

Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.